IP Library Granted Patent US 10,450,371
Granted Patent B2
US 10,450,371 · App. 15/787,237 · Granted Oct 22, 2019

Monoclonal antibody and antigens for diagnosing and treating lung disease and injury

Inventors: Matthias Clauss (Indianapolis, IN); Irina Petrache (Indianapolis, IN); Robert Voswinckel (Geissen, DE)
Assignees: Indiana University Research and Technology Corporation; United States Government as represented by the Department of Veterans Affairs
C07K16/22C07K16/18C07K16/2866A61K2039/505C07K2317/73C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,450,371
App. No.
15/787,237
Granted
Oct 22, 2019
Kind
B2
Abstract

The present invention provides methods for diagnosing a patient with emphysema, COPD of lung injury caused by tobacco use by detecting the levels of EMAP II in a sample. Disclosed herein are the hypervariable regions for a rat monoclonal antibody that binds to a form of EMAP II. This disclosure also includes a polypeptide sequence included in EMAP II that is the target for the binding of the antibody to its target protein. This epitope serves as the basis for a humanized antibody that can be used to treat patients that suffer from pathologies that exhibit elevated levels of EMAP II expression.

Claims (7)

1. A method of making an antibody, the method comprising the steps of:

contacting the immune system of a mammal with a polypeptide consisting of SEQ ID NO: 12; and

selecting a B-cell from the mammal;

wherein the B-cell produces antibodies that bind to endothelial monocyte activating protein II (EMAP II).

2. The method according to claim 1 , wherein contacting the immune system of the mammal comprises immunizing the mammal.

3. The method according to claim 1 , wherein selecting a B-cell from the mammal comprises isolating B-cells from the mammal, fusing the B-cells with myeloma cells thereby forming hybridomas, and selecting at least one hybridoma.

4. The method according to claim 3 , wherein the at least one hybridoma is selected by testing hybridoma supernatant for binding of EMAP II by enzyme linked immunosuppression assay (ELISA).

Continuity (3)
Division 14124439
Provisional Application 61494720 · Jun 8, 2011
Related Publication 20180111987A1 · Apr 26, 2018